Spots Global Cancer Trial Database for beam
Every month we try and update this database with for beam cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma | NCT00117455 | Non-Hodgkin's L... | pegfilgrastim filgrastim | 18 Years - | Amgen | |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | NCT05367856 | T Cell Lymphoma | Chidamide combi... | 18 Years - 65 Years | Ruijin Hospital | |
| A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma | NCT00117455 | Non-Hodgkin's L... | pegfilgrastim filgrastim | 18 Years - | Amgen | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) | NCT02278796 | Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... | BeEAM BEAM | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT | NCT02992223 | Refractory B-Ce... Recurrent B-Cel... | 19 Years - | Azienda Ospedaliera Città della Salute e della Scienza di Torino | ||
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) | NCT01827605 | Relapsed Follic... | ZEVALIN BEAM | 18 Years - 65 Years | Fondazione Italiana Linfomi - ETS | |
| Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma | NCT00574509 | Lymphoma | 131Iodine-Anti-... BEAM | 19 Years - 70 Years | University of Nebraska | |
| Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT | NCT05814718 | Autologous Stem... Conditioning | modified BEAM BEAM | 18 Years - 60 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma | NCT00572013 | Lymphoma | Rituxan BEAM Autologous stem... | 19 Years - | University of Nebraska | |
| VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | NCT00571493 | Non-hodgkin's L... Mantle Cell Lym... | Bortezomib BEAM (carmustin... | 19 Years - | University of Nebraska | |
| Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma | NCT01468311 | Hodgkin Disease Hodgkin Lymphom... | Auto stem cell ... BEAM 111In-daclizuma... 90Y-daclizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma | NCT01468311 | Hodgkin Disease Hodgkin Lymphom... | Auto stem cell ... BEAM 111In-daclizuma... 90Y-daclizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
